BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer
Author | Ismail, Tala |
Author | Alzneika, Safa |
Author | Riguene, Emna |
Author | Al-maraghi, Salwa |
Author | Alabdulrazzak, Aya |
Author | Al-Khal, Noof |
Author | Fetais, Sara |
Author | Thanassoulas, Angelos |
Author | AlFarsi, Halema |
Author | Nomikos, Michail |
Available date | 2024-05-21T10:34:44Z |
Publication Date | 2024-03-04 |
Publication Name | Pharmaceuticals |
Identifier | http://dx.doi.org/10.3390/ph17030333 |
Citation | Ismail, T., Alzneika, S., Riguene, E., Al-maraghi, S., Alabdulrazzak, A., Al-Khal, N., ... & Nomikos, M. (2024). BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer. Pharmaceuticals, 17(3), 333. |
Abstract | The BRCA1 is a tumor suppressor gene that encodes for the BRCA1 protein, which plays a vital role in DNA repair, cell cycle regulation, and the maintenance of genomic stability. The BRCA1 protein interacts with a variety of other proteins that play essential roles in gene regulation and embryonic development. It is a large protein composed of multiple domains. The C-terminal region of the BRCA1 protein consists of two BRCT domains connected by a short linker. The BRCT domains are crucial in protein–protein interactions as well as in DNA damage response and cell cycle regulation through their phosphoprotein binding modules that recognize the phosphorylated protein sequence motif of other kinases. Mutations within the BRCT domain can disrupt the normal function of BRCA1 and lead to an increased risk of developing breast and ovarian cancer. Herein, we explore the structural characteristics of BRCA1, focusing on the BRCT domain, its interactions with key cellular components, and its involvement in various cellular processes. In addition, the impact of BRCT domain mutations on breast and ovarian cancer susceptibility, prognosis, and treatment options is discussed. By providing a comprehensive understanding of the BRCT domain of BRCA1, this review aims to shed light on the role of this important domain in the pathogenesis and potential therapeutic approaches for breast and ovarian cancer. |
Sponsor | This work was supported by a UREP grant (grant No. UREP29-071-1-019) by QRDI. |
Language | en |
Publisher | Multidisciplinary Digital Publishing Institute (MDPI) |
Subject | BRCA1 gene BRCT domain breast cancer ovarian cancer |
Type | Article |
Issue Number | 3 |
Volume Number | 17 |
ESSN | 1424-8247 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1382 items ]